Pharma Focus Asia
KP - Sustainable Packaging Solutions

MaaT Pharma and Skyepharma Construct New Manufacturing Facility in Europe

Introduction

MaaT Pharma and Skyepharma have successfully completed the construction of Europe's largest manufacturing facility dedicated to microbiome ecosystem therapies. 

Features

This state-of-the-art facility spans an impressive 17,200 square feet and is specifically designed to support both clinical and commercial-scale manufacturing of microbiome ecosystem therapies.

The new facility not only enhances bioproduction capabilities but also makes a valuable contribution to the biotech ecosystem in France and Europe as a whole. 

The first production campaign is scheduled to commence in the new plant by the end of the third quarter of 2023. In addition, the facility will lead to the creation of around a dozen jobs, which is a positive development for the biopharmaceutical sector.

This signifies the start of a new era in the manufacturing of microbiome ecosystem therapies in Europe, with the potential to provide innovative treatment options for a wide range of medical conditions.

Specifications:

Name   MaaT Pharma and Skyepharma
Type   New Construction
 

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?